Chinese biotech startup Cure Genetics has secured $60 million in a Series B round. Separately, the country’s pharmaceutical firm Atom Bioscience has raised over 300 million yuan ($47.2 million) to fund the clinical development of its drug candidates.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
